NON CLEAR CELL RCC INCLUDED IN SUNITINIB EAP
‐
Tumor response (per RECIST), n (%)
Number of evaluable patients
All (n = 3353)
Non‐clear cell histology (n = 379)
OR
660 (16)
42 (8)
CR
63 (1)
4 (<1)
PR
597 (14)
38 (8)
SD ≥ 3 months
1893 (45)
217 (43)
PR or SD < 3 months
800 (19)
120 (24)
Clinical benefit*
2553 (61)
259 (51)
Summary of Median PFS and OS
Number of evaluable patients
All (n = 4543)
Non‐clear cell histology (n = 532)
PFS, months (median; 95% CI)
9.4 (8.8 – 10.0)
6.0 (5.4 – 7.0)
OS months (median; 95% CI)
18 7 (17 5 – 19 5)
12 2 (10 2 – 14 2)
,
.
.
.
.
.
.
69
Gore ME, et al. Br J Cancer 2015;113:12‐9
